BRD control: tying it all together to deliver value to the industry.

Pasteur described an organism causing fowl cholera in 1880. In 134 years we have progressed from crude vaccines for Pasteurella, to some refined vaccines, to a name change (Mannheimia), to autogenous vaccines (back to crude). In the last 25-30 years, we have attempted to mitigate the problem of bovine respiratory disease with antimicrobials and subsequently have a high incidence of multi-drug resistance. All of these attempts have resulted in little if any improvement in morbidity/mortality. Is it time to focus on the animal's response or lack of response to infectious pressure? Instead of focusing on the 10-50% morbid cattle should we focus on the 50-90% that are not compromised and determine why they stay healthy under the same environmental conditions?

Overview of the North American beef cattle industry and the incidence of bovine respiratory disease (BRD).

The North American beef cattle industry has endured many changes throughout the years but is encountering some of the most dramatic challenges in history during the first decade of the 21st century. The US beef cattle inventory increased from 1990 to a high of 103.5 million in 1996 and since has declined to a low of 94.5 million on 1 January 2009. Even though economic signals have encouraged the cow herd to increase over the last 5 years, a significant decrease occurred during 2008. It is difficult to determine the precise cost of bovine respiratory disease (BRD) to the industry but it is reported to be greater than US$500 million per year. Data from our practice indicate that losses from BRD over the last 18 years have been characterized by 5-year cycles of decreases and increases. Perhaps it is time for the industry to look for ways to reduce death loss by methods that focus on the animal's response to the pathogens instead of continuing to focus on the pathogens.